Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of authorized generic version of Bausch Health’s Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Investor Relations/Corporate M&A
General Manager – Corporate Communications
Apriso® is a registered trademark of Bausch Health Companies Inc.